Rocket Pharmaceuticals Inc
RCKT
Company Profile
Business description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Contact
9 Cedarbrook Drive
CranburyNJ08512
USAT: +1 609 659-8001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
202
Stocks News & Analysis
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,899.10 | 41.50 | -0.46% |
| CAC 40 | 8,436.24 | 43.63 | -0.51% |
| DAX 40 | 25,465.25 | 352.64 | -1.37% |
| Dow JONES (US) | 52,925.15 | 130.76 | -0.25% |
| FTSE 100 | 10,665.88 | 14.11 | 0.13% |
| HKSE | 23,886.34 | 389.45 | 1.66% |
| NASDAQ | 25,818.69 | 302.47 | -1.16% |
| Nikkei 225 | 67,758.64 | 498.32 | -0.73% |
| NZX 50 Index | 13,666.34 | 96.45 | -0.70% |
| S&P 500 | 7,503.85 | 33.58 | -0.45% |
| S&P/ASX 200 | 8,704.60 | 33.00 | -0.38% |
| SSE Composite Index | 3,989.66 | 0.57 | -0.01% |